<DOC>
	<DOCNO>NCT02585908</DOCNO>
	<brief_summary>In study , safety effect γδT cell human gastric cancer go investigate .</brief_summary>
	<brief_title>Safety Efficacy γδ T Cell Against Gastric Cancer</brief_title>
	<detailed_description>PBMC patient separate peripheral blood . After make potential cancer killer γδ T Cell CIK , infuse patient immunotherapy .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Age:3075 2 . Karnofsky performance status &gt; 50 3 . Diagnosis gastric cancer base histology current accept radiological measure . 4 . Classification tumor , node , metastasisclassification ( TNM ) stage : Ⅱ , Ⅲ , Ⅳ 5 . Patients life expectancy least 12 week 6 . Ability understand study protocol willingness sign write informed consent document 1 . Any significant medical psychiatric illness would prevent patient give informed consent follow study procedure . 2 . Known human immunodeficiency virus ( HIV ) infection . 3 . Active and/or severe infection ( e.g . tuberculosis , sepsis opportunistic infection , active hepatitis B virus ( HBV ) active hepatitis C virus ( HCV ) infection ) . 4 . Other serious underlie medical condition , , Investigator 's judgment , could impair ability patient . 5 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>